#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14434	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2026	706.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1681	1681	T	797	T	730	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14434	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2026	706.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1415	1415	C	910	C	829	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26434	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3635	725.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1693	1693	A	904	A,G	841,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26434	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3635	725.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2327	2327	C	842	C	777	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26434	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3635	725.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2401	2401	A	830	A	779	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26434	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3635	725.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2953	2953	C	852	C	776	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	27	1988	folP	852	852	99.88	folP.l15.c4.ctg.1	1369	144.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5130	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3312	154.0	1	SNP	p	S91F	0	.	.	271	273	TCC	580	582	TCC	181;182;184	T;C;C	160;164;166	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5130	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3312	154.0	1	SNP	p	D95G	0	.	.	283	285	GAC	592	594	GAC	183;183;184	G;A;C	163;163;166	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5130	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3312	154.0	1	SNP	p	D95N	0	.	.	283	285	GAC	592	594	GAC	183;183;184	G;A;C	163;163;166	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1448	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1298	111.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	464	466	ACC	174;168;169	A;C;C	156;152;155	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1448	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1298	111.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	662	664	CAC	195;196;197	C;A;C	181;183;185	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1448	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1298	111.0	0	.	p	.	0	E117K	NONSYN	349	351	GAA	698	700	AAA	201;200;196	A;A;A	185;185;178	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1448	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1298	111.0	1	SNP	p	G45D	0	.	.	133	135	GGC	482	484	GGC	173;174;176	G;G;C	158;159;162	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	860	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1138	75.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1489	1491	ATC	186;185;184	A,G;T;C	169,1;169;168	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1642	1644	GCA	166;166;165	G;C;A	152;152;150	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2125	2127	ATT	188;191;188	A,G;T;T	173,1;175;172	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	1	SNP	p	D86N	0	.	.	256	258	GAC	595	597	GAC	194;195;196	G,A;A;C	184,1;179;183	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	1	SNP	p	S87I	0	.	.	259	261	AGT	598	600	AGT	195;193;194	A;G;T	183;183;180	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	1	SNP	p	S87W	0	.	.	259	261	AGT	598	600	AGT	195;193;194	A;G;T	183;183;180	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	1	SNP	p	S87R	0	.	.	259	261	AGT	598	600	AGT	195;193;194	A;G;T	183;183;180	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4728	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2925	161.1	1	SNP	p	S88P	0	.	.	262	264	TCC	601	603	TCC	193;193;195	T;C;C	178;182;185	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4098	parE	1986	1986	99.95	parE.l15.c17.ctg.1	2519	161.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1454	1456	GGC	218;215;212	G;G;C	195;192;189	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1278	1280	GCA	229;233;233	G;C;A	206;207;211	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1281	1283	ATC	234;233;236	A;T;C	211;211;211	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1293	1295	GTG	234;233;234	G;T;G	210;210;212	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1293	1295	GTG	234;233;234	G;T;G	210;210;212	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1797	1799	ACC	228;227;230	A;C;C,A	204;208;208,1	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1851	1853	GCG	189;191;192	G;C;G	164;154;162	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1851	1853	GCG	189;191;192	G;C;G	164;154;162	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1974	1976	GGC	169;170;170	G;G;C	155;156;154	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1983	1985	GGC	167;164;162	G;G;C	152;148;144	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3938	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2411	162.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2001	2003	CCG	139;139;139	C,G,T;C;GCCC,GGCCCC	103,5,1;106;98,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5458	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3026	179.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2070	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1680	122.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	509	509	C	161	C	145	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	216	porB1a	984	188	90.1	porB1a.l6.c17.ctg.2	315	11.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	145	147	AAT	6;7;7	A;A;T	6;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	216	porB1a	984	188	90.1	porB1a.l6.c17.ctg.2	315	11.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	148	150	AAT	7;7;7	A;A;T	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	216	porB1a	984	188	90.1	porB1a.l6.c17.ctg.2	315	11.6	0	.	p	.	0	A222V	NONSYN	664	666	GCT	160	162	GTT	7;7;7	G;T;T	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	216	porB1a	984	188	90.1	porB1a.l6.c17.ctg.2	315	11.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	172	174	GCG	6;6;6	G;C;G	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	216	porB1a	984	188	90.1	porB1a.l6.c17.ctg.2	315	11.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	195	197	GTA	6;6;5	G;T;A	6;6;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	216	porB1a	984	188	90.1	porB1a.l6.c17.ctg.2	315	11.6	0	.	p	.	0	N237K	NONSYN	709	711	AAC	204	206	AAA	4;4;4	A;A;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	216	porB1a	984	188	90.1	porB1a.l6.c17.ctg.2	315	11.6	0	.	p	.	0	D238fs	FSHIFT	712	712	G	207	207	G	4	G	4	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2884	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1392	203.4	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	641	643	CAA	250;250;252	C,G;A,G;A	232,1;232,1;235	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2884	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1392	203.4	0	.	p	.	0	E212S	NONSYN	634	636	GAA	848	850	AGT	209;209;211	A;G;T	202;201;202	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2884	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1392	203.4	0	.	p	.	0	H213D	NONSYN	637	639	CAT	851	853	GAT	208;210;210	G;A;T	201;200;200	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2884	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1392	203.4	0	.	p	.	0	V215D	NONSYN	643	645	GTT	857	859	GAT	211;211;211	G;A;T	203;200;201	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2884	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1392	203.4	0	.	p	.	0	I218M	NONSYN	652	654	ATC	866	868	ATG	208;211;213	A;T;G	197;198;197	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2884	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1392	203.4	0	.	p	.	0	R257K	NONSYN	769	771	AGG	983	985	AAG	224;229;227	A;A;G	210;217;215	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2884	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1392	203.4	1	SNP	p	G120K	0	.	.	358	360	GGC	572	574	GGC	258;255;258	G,A;G,A;C,T,G	235,1;231,1;232,1,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11330	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4884	231.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1987	1989	CAT	251;251;252	C;A;T	234;237;236	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1206	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1090	110.0	1	SNP	p	V57M	0	.	.	169	171	GTG	497	499	GTG	276;274;275	G,A;T;G	253,1;251;252	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
